Developing drugs for the treatment of

Osteoporosis

About Us

Haoma Medica is a UK based biotech company that focuses on treatments for Osteoporosis and Osteopenia as well as blood clotting management. The Osteoporosis & Osteopenia drug referred to as NaQuinate and commercially as Osteopura, is a novel class of compound that has a new mechanism of action compared with existing treatments and is designed for low dose oral administration. The chemical compound, NaQuinate, occurs naturally within the body and appears to preserve both bone mass and bone architecture and thus the safety profile of this therapeutic approach has significant potential for the long-term treatment of the serious condition of Osteoporosis.

 

The active substance in Osteopura is present in all people, but only in very small amounts. Osteopura boosts the levels of this naturally occurring compound to preserve bone integrity. Haoma Medica started with the platform of “working with nature and not against it”.   

NaQuinate 

A novel therapeutic for the treatment of Osteoporosis

Anticipated Strengths of NaQuinate

  • Novel class of compound

  • Unique mechanism of action

  • Product naturally occuring in the body

  • Small molecule

  • Low toxicity

  • Low dosage

  • Ability to improve bone quality not just quantity

  • Non gender specific 

  • Administered orally

  • ‘Quick On, Quick Off'

  • Inexpensive to manufacture

  • Beneficial additional effects

Inhibits bone loss in a pharmaceutical industry “Gold Standard” animal model of postmenopausal osteoporosis. The market is ready for a novel treatment with a new mechanism of action in the management of patients at risk of fracture; one that addresses the unmet need for a therapy with better efficacy in the treatment and prevention of long bone fractures, and one that provides anabolic characteristics but with a better safety profile. We believe NaQuinate and Osteopura can meet these requirements.

 

Patent Update

Haoma Medica has three patents, two have been granted and one is pending grant. They cover the following countries: UK, US, Canada, Australia, Japan, Korea, Hong Kong, Russia, India, China, Brazil, Isreal and the European zone

Pre-Clinical 

Our current strategy within the early clinical development phase is focused on identifying and understanding more about NaQuinate’s unique mechanism of action compared with all current treatments and its ability to improve bone quality not just quantity.

Phase I

We have completed our first in human study. This was a single and multiple ascending dose study to evaluate the safety, tolerability and pharmacokinetics of varying doses of NaQuinate in healthy subjects. A full press release is available on our Press Release page.

Phase Ib

Phase Ib Study in Healthy Post-Menopausal Women has been initiated. It is designed as a randomised, double-blind, placebo-controlled parallel group study to investigate the safety, tolerability, pharmacokinetic and pharmacodynamic effects of NaQ in healthy post-menopausal women with low bone mineral density. The objective is to study the safety and tolerability of NaQ with longer term treatment (28 days) in our target subject demographic prior to a 2-year treatment patient study in post-menopausal women with osteoporosis. In addition, the study will help to confirm a bone pharmacodynamic effect in humans.

Phase II

Our proposed Phase II study combines the objectives of a Phase IIa proof of concept study in patients with osteoporosis and osteopenia and a Phase IIb dose ranging study to help select doses for Phase III pivotal registration trials. More advanced technologies such as quantitative computed tomography (QCT) and High Resolution peripheral QCT will be used to evaluate the effects of treatment on different bone compartments and at a level that can evaluate drug treatment effects on bone geometry and microarchitecture (for e.g. cortical thickness and cortical porosity). Estimates of bone strength in patients will also be assessed using finite element analysis. We expect to initiate the Phase II program for Osteoporosis later in 2020.

News

 

LONDON, Nov. 26, 2020-- Haoma Medica announced today the completion of a first-in-human trial for NaQuinate, a naphthoquinone carboxylic acid, which is being developed as a novel orally administered therapeutic for osteoporosis. 

''We are delighted that the first-in-human study has completed its last dosing. There were no significant safety or tolerability concerns up to the highest doses tested which underlines our expectation that NaQuinate is safe and well tolerated,'' said Dr Cenk Oguz, Haoma Medica's Chief Medical Officer.

'Our pre-clinical research has revealed an exciting feature of NaQuinate where it appears to have the capacity to work in harmony with the body's natural response to weight bearing exercise to synergistically enhance bone formation when and where required – now that would be a 'smart' drug,' said Dr Steve Deacon, Haoma Medica's CEO. 'Together with the safety data from this first-in-human study, this supports the potential that NaQuinate treatment could provide a safe, novel and smart therapeutic approach to bone disorders like osteoporosis and better maintain healthy skeletal aging.

Fund Raising

Series A Raise

Haoma Medica will look to raise a Series A funding round in Q1, 2021. This will provide funding for additional Pre-Clinical research and begin Phase II trials.

Please contact us should you be interested in investing in Haoma Medica's Seed B and/or Series A raise. We would be prepared to discuss details of the raise as early as November, 2020.

Contact Information

Office Phone  (+44) 0207 629 1954

LBIC Phone    (+44) 0189 526 5540

Emails

info@haomamedica.com

stephen.hodges@haomamedica.com (CSO)

stephen.deacon@haomamedica.com (CEO)

carmen.greco@haomamedica.com (CFO)

cenk.oguz@haomamedica.com (CMO)

Mailing Address

Haoma Medica Ltd.

c/o London BioScience Innovation Centre

2 Royal College Street 

London, England

United Kingdom

NW1 0NH

LinkedIn Haoma Medica

Company Registration GB No. 06784000